Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced the pub [...]
AI biomarker predictive of long-term ADT benefit in patients with prostate cancer
Investigators have validated the first AI-derived predictive biomarker of long-term androgen deprivation therapy (ADT) benefi [...]
ASCO 2023: AI-Derived Digital Pathology Biomarker Predicts Benefit of Long-Term ADT with Radiotherapy in Localized High-Risk Prostate Cancer
Dr. Andrew J. Armstrong presented the results of a pooled analysis of multiple phase III NRG/RTOG trials aimed at developing [...]
Mack Roach, MD, FASTRO, FASCO
Dr. Roach discusses how the performance of the multimodal artificial intelligence (MMAI)-derived prognostic biomarker is comp [...]
Daniel Spratt, MD
Dr. Spratt discusses the validation of an MMAI prognostic biomarker and how the model further stratifies risk in men with hig [...]
Osama Mohamad, MD
Dr. Mohamad discusses the development and validation of a multimodal artificial intelligence (MMAI)-derived prognostic biomar [...]
Daniel Spratt, MD
Dr. Spratt discusses the validation of an MMAI prognostic biomarker and how the model further stratifies risk in men with hig [...]
Prostate cancer therapy personalization via multi-modal deep learning on randomized phase 3 clinical trials.
Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient’s optimal thera [...]
Ashley Evan Ross, MD, PHD
Dr. Ross discusses external validation of an MMAI prognostic model in patients with high- and very high-risk disease. Additio [...]